Top Page
Organigram Global
(TSX:OGI)
Organigram Global (OGI) vs. iShares MSCI Canada ETF (EWC)
Organigram Global Business Overview & Revenue Model
Organigram Global Earnings Call Summary
Organigram Global Financial Statement Overview
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 279.99M | 259.18M | 159.84M | 149.21M | 145.81M | 79.16M |
| Gross Profit | 19.01M | 9.51M | 47.52M | 35.07M | 31.57M | -28.40M |
| EBITDA | -15.58M | -20.55M | -23.59M | -207.62M | 10.96M | -95.59M |
| Net Income | 18.17M | -24.76M | -45.44M | -229.48M | -14.28M | -130.70M |
Balance Sheet | ||||||
| Total Assets | 530.67M | 562.21M | 407.86M | 298.45M | 577.11M | 554.02M |
| Cash, Cash Equivalents and Short-Term Investments | 8.38M | 84.42M | 107.57M | 33.86M | 98.91M | 183.84M |
| Total Debt | 8.45M | 8.75M | 4.46M | 4.72M | 3.36M | 4.96M |
| Total Liabilities | 161.22M | 213.08M | 101.87M | 26.83M | 69.05M | 74.21M |
| Stockholders Equity | 369.46M | 349.13M | 305.99M | 271.62M | 508.06M | 479.81M |
Cash Flow | ||||||
| Free Cash Flow | -36.81M | -24.64M | -1.47M | -62.70M | -84.99M | -40.92M |
| Operating Cash Flow | -19.29M | -7.59M | 3.87M | -35.80M | -36.21M | -28.59M |
| Investing Cash Flow | -23.99M | -82.67M | -38.77M | 1.35M | 44.03M | -115.11M |
| Financing Cash Flow | 39.09M | 39.33M | 107.78M | -817.00K | 5.33M | 174.46M |
Organigram Global Technical Analysis
Organigram Global Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$2.07B | 16.23 | 6.18% | ― | 6.18% | -28.69% | |
60 Neutral | C$1.35B | -104.58 | -0.88% | ― | 22.20% | ― | |
52 Neutral | C$282.98M | 44.94 | -16.05% | ― | 23.87% | -19.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$2.41B | -8.05 | -27.48% | ― | -3.38% | -31.35% | |
47 Neutral | C$252.70M | 3.90 | 4.77% | ― | 62.15% | 60.50% | |
46 Neutral | C$532.42M | -2.15 | -47.80% | ― | -0.67% | 58.98% |
Organigram Global Corporate Events
Organigram has agreed to acquire all remaining shares of Berlin-based Sanity Group, one of Europe’s leading cannabis companies, for upfront consideration of €113.4 million and potential earnouts of up to €113.8 million tied to post-closing performance. The deal, funded through cash, a new credit facility and an expected C$65.2 million equity investment from BAT, will combine two market leaders across medical cannabis, recreational pilot programs and wellbeing products in the world’s two largest federally legal cannabis markets.
Sanity Group, founded in 2018, has rapidly scaled annual net revenue from €9 million in 2023 to €60 million in 2025 and operates Europe’s first two legal cannabis specialty stores under Swiss pilot projects. By adding Sanity’s strong German platform, planned entries into the U.K. and Poland, and existing business in Czechia, Organigram positions itself to sell larger volumes of higher-margin flower into Europe, deepen its supply-chain network, and extend its product IP into emerging legal cannabis markets, strengthening its competitive footing in a fast-growing European sector.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram posted strong first-quarter fiscal 2026 results, with gross revenue rising 46% to $97.3 million and net revenue up 49% to $63.5 million, driven by the Motif Labs acquisition and higher international sales. The company retained leading Canadian market share across key product categories, boosted adjusted EBITDA to $5.3 million, and turned a $20 million net profit from a loss a year earlier on improved margins and financial instrument revaluations.
Operationally, Organigram expanded its U.S. footprint to 11 states with its Collective Project and Fetch brands while flagging that recent U.S. federal hemp law changes could force a restructuring of its hemp-derived THC activities by late 2026 if not reversed. The firm also reported a 43% increase in harvested kilograms and a genetic breakthrough in powdery mildew resistance that should enhance yield stability and reduce production costs, underscoring its emphasis on efficiency, plant science and international growth under new CEO James Yamanaka.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Global Inc., Canada’s leading cannabis company by market share with extensive cultivation, processing and branded product operations across multiple provinces, will release its first quarter fiscal 2026 results, covering the period ended December 31, 2025, on February 10, 2026, before markets open. The company will host an earnings conference call and webcast the same morning to discuss its performance, with a replay available to investors for 90 days, underscoring Organigram’s ongoing efforts to maintain transparency with the market as it executes on its growth strategy in cannabis and cannabinoid beverages.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Global Inc. has expanded its innovation partnership with cannabis genetics specialist Phylos Bioscience Inc. through an amended loan and product agreement that strengthens its leadership in seed-based cultivation and provides a long-term pipeline of next-generation cannabis genetics. The deal includes a new US$3 million advance, bringing Organigram’s total loan to Phylos to US$10 million, and secures priority access to Phylos’ autoflower genetics pipeline, with 30 new genetics to be delivered twice annually through 2030 for both recreational and medical markets. Organigram gains five-year exclusive rights to selected autoflower cultivars in key international markets including Canada, Australia, the UK, Germany and Israel, with the ability to add territories as it expands globally, bolstering product differentiation and supporting its entry into high-value medical markets. The agreement is expected to enhance operational security, consistency and scalability in cultivation, while giving Organigram an economic and competitive edge as the first mover deploying scientifically bred F1 hybrid seeds at commercial scale.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram reported record financial results for the fourth quarter and fiscal year 2025, with significant increases in revenue and adjusted EBITDA. The company maintained its leadership in the Canadian cannabis market and expanded its international sales. Notable achievements include the acquisition of Motif Labs and Collective Project, advancements in genomics R&D, and a record harvest. However, potential challenges arise from U.S. legislative changes affecting hemp-derived THC products, which may impact Organigram’s operations in the U.S.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Holdings has appointed James Yamanaka, former Global Head of Strategy at British American Tobacco, as its new CEO, effective January 15, 2026. Yamanaka’s extensive experience in strategy and management is expected to bolster Organigram’s global aspirations, leveraging his track record of driving international growth and transforming businesses to enhance the company’s position in the cannabis industry.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.